Galapagos NV (NASDAQ:GLPG) Receives Consensus Recommendation of “Reduce” from Analysts

Shares of Galapagos NV (NASDAQ:GLPG) have been given an average rating of “Reduce” by the eight analysts that are covering the firm, MarketBeat.com reports. Four analysts have rated the stock with a sell rating and four have issued a hold rating on the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $25.33.

Several research firms recently commented on GLPG. Barclays reissued an “underweight” rating on shares of Galapagos in a report on Thursday, January 23rd. TD Cowen downgraded Galapagos from a “strong-buy” rating to a “strong sell” rating in a report on Thursday, January 9th. Finally, Morgan Stanley lowered Galapagos from an “equal weight” rating to an “underweight” rating and cut their target price for the stock from $31.00 to $22.00 in a research report on Friday, February 14th.

Galapagos Trading Down 1.1 %

NASDAQ GLPG opened at $24.50 on Friday. Galapagos has a 52 week low of $22.36 and a 52 week high of $32.17. The firm has a 50 day moving average of $25.12 and a two-hundred day moving average of $26.82.

Institutional Trading of Galapagos

A number of institutional investors have recently modified their holdings of GLPG. R Squared Ltd acquired a new position in shares of Galapagos during the 4th quarter worth $26,000. GAMMA Investing LLC increased its holdings in Galapagos by 77.4% during the 4th quarter. GAMMA Investing LLC now owns 2,233 shares of the biotechnology company’s stock valued at $61,000 after acquiring an additional 974 shares in the last quarter. BNP Paribas Financial Markets raised its position in Galapagos by 45.9% during the fourth quarter. BNP Paribas Financial Markets now owns 8,972 shares of the biotechnology company’s stock worth $247,000 after acquiring an additional 2,824 shares during the last quarter. QRG Capital Management Inc. lifted its holdings in shares of Galapagos by 21.7% in the fourth quarter. QRG Capital Management Inc. now owns 10,455 shares of the biotechnology company’s stock valued at $288,000 after purchasing an additional 1,866 shares in the last quarter. Finally, Wealthedge Investment Advisors LLC purchased a new position in Galapagos in the 4th quarter valued at about $311,000. 32.46% of the stock is currently owned by hedge funds and other institutional investors.

About Galapagos

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.